Toni K. Choueiri, MD - RCC MasterClass and Clinical Consult: Remodeling the Treatment Algorithm With Novel Immune and Targeted Therapies

1:16:36
 
シェア
 

Manage episode 291205231 series 9912
著作 PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education の情報はPlayer FM及びコミュニティによって発見されました。著作権は出版社によって所持されます。そして、番組のオーディオは、その出版社のサーバから直接にストリーミングされます。Player FMで購読ボタンをタップし、更新できて、または他のポッドキャストアプリにフィードのURLを貼り付けます。
Go online to PeerView.com/QEY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of renal cell carcinoma (RCC) continues to expand rapidly with the addition of novel multi-targeted tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor therapies. The long-term data supporting the efficacy of dual checkpoint blockade, together with further follow-up reported for established immunotherapy-TKI partners, as well as new efficacious combinations, has increased the number of treatment choices in the frontline setting of advanced RCC. Oncologists and other healthcare professionals who manage patients with RCC are being called upon to apply these novel immune and targeted strategies in a patient-centric manner. During this PeerView CME/MOC-certified activity, an expert faculty panel will share the clinical science and current evidence on novel targeted and immunotherapeutic strategies in the upfront and previously treated advanced RCC settings. Upon completion of this activity, participants should be better able to: Summarize the latest efficacy and safety data on new treatment approaches for advanced and/or resectable renal cell carcinoma (RCC), including targeted tyrosine kinase inhibitors, immune checkpoint inhibitors, and novel combination approaches, Select optimal frontline treatment options, such as dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors, for individual patients with advanced RCC based on the latest clinical evidence and relevant patient- and disease-related factors, Apply new clinical trial evidence to the selection and sequencing of novel agents and combination therapies for individual patients with advanced RCC that have progressed after one or more previous lines of therapy, taking into account patient treatment history and comorbidities, Employ effective strategies to proactively mitigate and manage adverse events related to targeted and immune-based therapies for advanced RCC.

478 つのエピソード